CYP2C19 Testing Post-PCI Slashes Heart Risk
from Pharmacy Practice News
Percutaneous coronary intervention guidelines do not recommend basing post-procedure clopidogrel therapy on cytochrome P450 2C19 genotype, but a study from the University of Florida suggests that may be a dangerous oversight. Investigators there conducted CYP2C19 genotyping in nearly 300 PCI patients and found that the testing enabled them to virtually eliminate the major cardiovascular events that can occur when patients with the genotype — and who thus are poor clopidogrel metabolizers — are given the anti-platelet agent.
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063